Abstract | BACKGROUND: METHODS: In this single-blind study, 10 patients with autonomic neuropathy and constipation were treated with placebo (2 weeks), followed by an escalating dose of pyridostigmine to the maximum tolerated dose (i.e., 180-540 mg daily) for 6 weeks. Symptoms and gastrointestinal transit were assessed at 2 and 8 weeks. The acute effects of neostigmine on colonic transit and motility were also assessed. RESULTS: At baseline, 4, 6, and 3 patients had delayed gastric, small intestinal, and colonic transit respectively. Pyridostigmine was well tolerated in most patients, improved symptoms in 4 patients, and accelerated the geometric center for colonic transit at 24 h by > or =0.7 unit in 3 patients. The effects of i.v. neostigmine on colonic transit and compliance predicted (P < 0.05) the effects of pyridostigmine on colonic transit. CONCLUSIONS:
|
Authors | Adil E Bharucha, Phillip A Low, Michael Camilleri, Duane Burton, Tonette L Gehrking, Alan R Zinsmeister |
Journal | Clinical autonomic research : official journal of the Clinical Autonomic Research Society
(Clin Auton Res)
Vol. 18
Issue 4
Pg. 194-202
(Aug 2008)
ISSN: 0959-9851 [Print] Germany |
PMID | 18622640
(Publication Type: Controlled Clinical Trial, Journal Article, Research Support, N.I.H., Extramural)
|
Chemical References |
- Cholinesterase Inhibitors
- Neostigmine
- Pyridostigmine Bromide
|
Topics |
- Adolescent
- Adult
- Aged
- Autonomic Nervous System
(drug effects)
- Autonomic Nervous System Diseases
(complications, drug therapy, physiopathology)
- Cholinesterase Inhibitors
(administration & dosage, therapeutic use)
- Constipation
(drug therapy, etiology, physiopathology)
- Female
- Gastrointestinal Transit
(drug effects)
- Humans
- Male
- Middle Aged
- Neostigmine
(administration & dosage, therapeutic use)
- Pilot Projects
- Pyridostigmine Bromide
(administration & dosage, adverse effects, therapeutic use)
- Single-Blind Method
|